Auteurs
Deal CL - Tony M - Höybye C - Allen DB - Tauber M - Christiansen JS -
Journal
The Journal of clinical endocrinology and metabolism
Abstract
Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events.